The Federal Government of Nigeria has successfully vaccinated over 3.9 million girls aged between 9 and 14 years against the Human Papilloma Virus (HPV), the primary cause of cervical cancer.
The vaccination campaign, which began in October, aims to reach 7.7 million girls in the targeted age group with a single dose of the HPV vaccine.
Dr. Garba Rufai, Acting Director of Disease Control and Immunisation at the National Primary Healthcare Development Agency (NPHCDA), reported that the vaccination has been well-received, with no serious adverse events recorded among those vaccinated. He emphasized that the vaccines were accepted in significant numbers, and the government is on track to achieve its vaccination goals.
The HPV vaccine was introduced into the routine immunization system, and the government aims to complete the vaccination campaign in the targeted states. Dr. Rufai highlighted that the country is building capacity and implementing monitoring and surveillance systems to ensure vaccine safety.
However, Professor Oyewale Tomori, a renowned virologist, and former Vice-Chancellor of Redeemer’s University, expressed concerns about gaps in information communication regarding the HPV vaccine. He emphasized the importance of early awareness and aggressive counteraction of false information to ensure the success of vaccination campaigns.
Professor Rose Anorlu, a Consultant Obstetrician and Gynecologist at the College of Medicine, University of Lagos, highlighted the significance of cervical cancer screening in preventing the disease. She emphasized that awareness and correct information are crucial for prevention, and the HPV vaccine is a primary preventive measure.
The virtual discourse on “Cervical Cancer and HPV vaccination: Matters Arising” was organized by the Network of Reproductive Health Journalists of Nigeria (NRHJN) with support from Marie Stopes International of Nigeria (MSION).
